Johnson & Johnson, along with its orthopedic company, DePuy Synthes, saw multiple product advancements and growth in the third quarter.
Four notes:
1. DePuy Synthes has launched a new lower extremity anatomic plating system.
2. Johnson & Johnson's medtech business has seen volumes normalize, and orthopedic sales are seeing growth driven by enabling technologies, leaders said in a July 17 earnings call. The orthopedic segment saw key growth in its total joint revenue including hips and knees. Along with implants, enabling technologies like the Velys hip navigation and Kincise automated system have helped bolster orthopedic growth, Tim Schmid, executive vice president and worldwide medtech chair, said in the call.
3. DePuy Synthes earned FDA 510(k) clearance for and launched Velys Spine. Velys Spine is a dual-use robotics and standalone navigation platform created in collaboration with eCential Robotics. It is designed to plan and instrument spinal fusions.
4. LifeNet Health, in partnership with Johnson & Johnson MedTech, launched the PliaFX Pak bone allograft in the U.S. The bone graft includes a proprietary formula of bone chips and demineralized cortical fibers processed with PliaFX's fiber technology. It can be moldable once rehydrated without the need for a carrier, and it has numerous contact points for platelet attachment.